Ignite Creation Date:
2025-12-25 @ 12:33 AM
Ignite Modification Date:
2025-12-30 @ 6:17 PM
Study NCT ID:
NCT02691767
Status:
COMPLETED
Last Update Posted:
2022-06-15
First Post:
2016-02-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
Sponsor:
Samsung Medical Center
Organization:
Study Overview
Official Title:
Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
Status:
COMPLETED
Status Verified Date:
2022-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single arm, pilot study of pazopanib in patient with FGFR2 amplification Refractory solid tumor and/or specific sensitivity to pazopanib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy.
To investigate the efficacy and safety of pazopanib in patient with Refractory solid tumor.
To investigate the efficacy and safety of pazopanib in patient with Refractory solid tumor.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: